Oracle Has a Growth Opportunity That Goes Beyond Its Cloud Business


Published November 18, 2026, 9:33am ET · 4 min read

Price Targets desk. Editor: Vandita Jadeja.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Oracle monument sign standing on a lawn at the campus entrance, reading "ORACLE" and "Santa Clara Campus"
© maybefalse / Getty Images

The 24/7 Wall St. price target for Oracle (NYSE:ORCL | ORCL Price Prediction) is $191.42. That implies 60.73% upside from the latest close of $119.09. The stock earns a buy rating with high confidence.

An infographic titled '12-Month Price Prediction: Oracle (NYSE: ORCL)' from 24/7 Wall St. The top section shows a green arrow indicating '+60.73% UPSIDE' to a price target of $191.42 from a current price of $119.09, with a 'BUY High Confidence' rating. A methodology section details a weighted base of $168.21 derived from Trailing P/E (20% at $119.09), Forward P/E (50% at $147.07), and Analyst Target (30% at $236.18). An adjustment section illustrates how the base of $168.21 is adjusted by a +1.138x factor to reach the final target of $191.42, influenced by analyst consensus, earnings growth, sector momentum, and mega-cap dampening. Below, a 'Bull Case: What Could Go Right' section lists a target of $258.07, citing AI-Powered EHR adoption, multicloud database revenue growth, and AI agents in production. A 'Bear Case: What Could Go Wrong' section shows a target of $163.48, listing negative free cash flow, increased interest expense, and equity dilution. The bottom line reiterates the 'BUY Price Target: $191.42 (+60.73%)' with a concluding statement about Oracle's growth opportunities in AI infrastructure and healthcare software. The infographic uses a color palette of dark blue, light blue, white, green, and red.
24/7 Wall St.

24/7 Wall St. Price Target Summary

Metric Value
Current Price $119.09
Price Target from 24/7 Wall St. $191.42
Upside/Downside 60.73%
Recommendation BUY
Confidence Level 90%
ORCL price target

Oracle’s AI infrastructure business gets most of the attention. Healthcare software, the AI Data Platform and multicloud database revenue are building a second layer of growth that today’s valuation barely prices in.

Shares Down 38.58% in 2026 While Guidance Keeps Rising

Oracle shares are down 1.38% over the past week, 7.87% over the past month and 38.58% year to date. The stock sits 52.07% below its 52-week high of $248.46 and only 9.05% above its $109.21 low.

Funding worries explain much of the drop. Oracle priced $20 billion of common stock and senior notes[1] on November 3, shortly after completing a separate $20 billion[2] at-the-market equity program.

The business results tell a stronger story. Fiscal Q1 2027 non-GAAP EPS of $1.92[2] beat the $1.7391 consensus. Revenue rose 29.61%[2] to $19.345 billion, ahead of the $19.129 billion estimate. Remaining performance obligations (contracted revenue not yet recognized) reached $664 billion[2]. Management also raised full-year guidance to at least $90 billion[2] in revenue and $8.10 in non-GAAP EPS.

ORCL price scenario

Healthcare and Enterprise AI Could Push Oracle Toward $258

The bull case of $258.07 assumes Oracle earns AI revenue well beyond renting out GPU capacity. Management expects Oracle Health to grow at a double-digit[3] rate in fiscal 2027, driven by its new AI-based Cerner system. Shore Medical Center chose Oracle Health’s AI-powered EHR (electronic health record) on November 16[1].

On November 13[1], the Department of Veterans Affairs and the Department of War went live on the Oracle Health Information Network. Management said healthcare go-lives that once took “high double-digit months”[4] now take single-digit months.

The AI Data Platform gives Oracle another way to grow. On the September earnings call, CEO Michael Sicilia said it is “agnostic and able to pull in and automate the ontologies from any data source.”[4]

Multicloud database revenue grew 353%. Customers ran more than 2,300[4] AI agents in production, up 90% from the prior quarter. Wall Street’s consensus target of $236.18 is close to our bull case.

ORCL analyst ratings

Capital Intensity Remains Oracle’s Biggest Risk

The bear case of $163.48 still sits above today’s price, which shows how much pessimism is already in the stock. Free cash flow was -$5.396 billion[2] in Q1. Interest expense rose 55%[2], and software revenue fell 3%. Repeated equity raises also dilute existing shareholders.

There are counterpoints. Management says many new contracts rely on prepayments or customer-supplied hardware and need no extra Oracle capital.

CFO Hilary Maxson expects projects to reach free cash flow conversion of “something like 100% of post-tax EBITDA”[4] once they ramp up. The software decline partly reflects customers moving to the cloud, which now makes up 60%[2] of revenue.

Oracle Trades at a Steep Discount to Microsoft and Amazon

Microsoft (NASDAQ:MSFT) is Oracle’s most direct competitor in hyperscale cloud and enterprise AI. Azure grew 48% last quarter, and Microsoft trades at roughly 29x earnings. Oracle’s infrastructure business is growing faster at a lower multiple.

Amazon (NASDAQ:AMZN) is the AWS comparison. AWS grew 39%, yet Amazon carries trailing free cash outflow of $42.4 billion. Greatest capital spending is the norm across the industry, so Oracle’s spending alone does not explain its discount.

Company Trailing P/E Cloud Growth (Latest Quarter)
Oracle 19 121%[2] (OCI)
Microsoft 29 48% (Azure)
Amazon 36 39% (AWS)

Against these peers, the 24/7 Wall St. price target looks reasonable and arguably conservative.

Oracle’s Discount Looks Too Steep to Ignore

The 24/7 Wall St. price target is $191.42, with a buy rating and 90% confidence. Valuation is the deciding factor. The stock trades at a forward P/E of 15 while its growth rate keeps improving.

I would view the case as stronger if Oracle shows a clear path to positive free cash flow and Oracle Health turns its AI-powered EHR deals into revenue. I would grow more cautious if another equity raise comes before contracted revenue starts converting faster. The next checkpoint is the earnings report on December 14, 2026[4].

The model projects where Oracle could trade in the coming years if current growth trends and market conditions hold:

Year Price Target from 24/7 Wall St.
2026 $191.42
2027 $190.92
2028 $262.98
2029 $329.26
2030 $392.51

The projections rest on Oracle continuing to execute its current strategy. The result could land well above or below these figures depending on how quickly Oracle’s $664 billion[2] backlog turns into revenue and whether its funding needs ease.

Contact [email protected] for any questions or corrections.

Vandita Jadeja

Vandita Jadeja is a financial publisher with over a decade of experience writing about financial topics, including investment, savings, retirement, insurance and banking. Vandita is a Chartered Accountant who loves to debunk financial concepts for readers.

Her work has appeared on sites that include The Motley Fool, InvestorPlace, and Benzinga. She covers investing and focuses on stock picks and price prediction for 24/7 Wall St.

When not looking for the next stock investment opportunity, she can be found traveling, reading, chasing sunsets and enjoying her iced latte.

All articles →

Sources

  1. PR NewswirePR Newswire
  2. Oracle Form 8-K (Q1 FY2027)U.S. Securities and Exchange Commission
  3. Oracle Form 8-K (Q4 FY2026)U.S. Securities and Exchange Commission
  4. Oracle Corporation Q1 2027 earnings callOracle Corporation